A groundbreaking new review comprehensively synthesizes the latest developments in next-generation chimeric antigen receptor T cell (CAR-T) therapies, highlighting key preclinical and clinical breakthroughs in the treatment of lymphoma. The article examines barriers to CAR-T efficacy and provides an in-depth analysis of innovative strategies, including multi-specific CAR, T cells redirected for universal cytokine-mediated killing (TRUCKs), switch receptor CAR, safety switch/suicide system, and in vivo CAR-T cells. With a special focus on the role of epigenetics and metabolism in CAR-T cell exhaustion, the review offers valuable insights and future directions for advancing CAR-T immunotherapy.

 Bispecific antibodies (bsAbs) refer to antibodies that bind two different antigens or epitopes simultaneously, which can enhance the targeting of antibodies and the efficacy of cancer treatments. Recent studies indicate that bsAb is a promising first-line or later-line treatment for non-small cell lung cancer (NSCLC) patients and may overcome treatment resistance. This study explores the classification, mechanisms of action and clinical application of bsAbs in the treatment of NSCLC.

Researchers from the Université Libre de Bruxelles (ULB) have discovered the cellular reprograming leading to prostate cancer initiation

Cancer Research UK-funded scientists at the University of Cambridge create a test to predict resistance to chemotherapy. The test uses changes to cancer DNA at diagnosis to predict which patients will be resistant to three common types of chemotherapy. New method could benefit thousands of patients every year by helping them avoid treatments that are less likely to benefit them.